Abeona Therapeutics Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

FAIR VALUE MEASUREMENTS (Tables)

FAIR VALUE MEASUREMENTS (Tables)

6 Months Ended

Jun. 30, 2023

SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS

The following table provides a summary of financial assets measured at fair value on a recurring and non-recurring basis as of June 30, 2023 and December 31, 2022 (in thousands):

Description	Fair Value at June 30, 2023		Level 1		Level 2		Level 3

Recurring Assets
Cash equivalents
Money market fund	$	5,678	$	5,678	$	—	$	—
Short-term investments
U.S. treasury and federal agency securities		30,547		—		30,547		—
Total assets measured at fair value	$	36,225	$	5,678	$	30,547	$	—

Liabilities
Warrant liabilities	$	26,021		—		—	$	26,021
Total liabilities measured at fair value	$	26,021	$	—	$	—	$	26,021

Description	Fair Value at December 31, 2022		Level 1		Level 2		Level 3

Recurring Assets:
Cash equivalents
Money market fund	$	12,923	$	12,923	$	—	$	—
Short-term investments
U.S. treasury and federal agency securities		37,932		—		37,932		—
Total assets measured at fair value	$	50,855	$	12,923	$	37,932	$	—

Liabilities
Warrant liabilities	$	19,657		—		—	$	19,657
Total liabilities measured at fair value	$	19,657	$	—	$	—	$	19,657

SCHEDULE OF ESTIMATE FAIR VALUE OF WARRANTS

	June 30, 2023		December 31, 2022

Common share price		$4.03		$3.08
Expected term (years)		3.47 – 4.35		3.96 – 4.84
Risk-free interest rate (%)		4.13% – 4.28%		3.91% – 4.01%
Volatility (%)		100.00% – 105.04%		102.40% – 107.55%

SCHEDULE OF ACTIVITY OF WARRANT LIABILITIES

The following table provides a summary of the activity on the warrant liabilities (in thousands):


Warrant liabilities as of December 31, 2022	$	19,657
Loss recognized in earnings from change in fair value		6,364
Warrant liabilities as of June 30, 2023	$	26,021